Le Lézard
Classified in: Health, Science and technology
Subjects: Corporate Social Responsibility, Award

Agilent Named Industry Leader in 2019 Dow Jones Sustainability Index


Agilent Technologies, Inc. (NYSE: A) today announced that for the fifth year in a row, the company has been named the industry leader in the Life Sciences Tools and Services category of the 2019 Dow Jones Sustainability Index (DJSI).

"Agilent's mission ? to improve the quality of life ? is the north star for our business, and we're pleased the Dow Jones Sustainability Index recognizes our accomplishments across a wide range of sustainability measures," said Mike McMullen, Agilent president and CEO. "It's an honor to again be recognized among the top companies included in this important measure of sustainability leadership."

The DJSI is in its 20th year providing investors, companies and others with information on corporate performance across a range of environmental, economic and social issues. The index is a joint venture between S&P Dow Jones Indices and RobecoSAM, a leader in sustainability ratings.

In 2019, more than 3,500 companies across 61 industries were invited to participate in a corporate sustainability assessment, tracking their performance in codes of business conduct, supply chain management, innovation management, corporate governance, operational eco-efficiency, environmental reporting, climate strategy, talent attraction and retention, and human capital development. Agilent's total score in the Life Sciences Tools and Services industry was more than double the average for the industry.

Details on Agilent's listing on the DJSI may be found on the RobecoSAM website. For additional information on Agilent's activities in corporate social responsibility, please see our 2019 CSR report.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 15,500 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom.

Follow Agilent on LinkedIn, Twitter, and Facebook.


These press releases may also interest you

at 19:35
CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS, A FLEXIBLE, LOW-MOQ, NUTRACEUTICAL MANUFACTURER
CV Sciences, Inc.  (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced that it has consummated...

at 19:32
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy...

at 19:21
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug...

at 18:30
Cannabix Technologies Enters into Marketing Agreements  
Cannabix Technologies Inc. (the "Company or Cannabix") reports that it has entered into an arm's length marketing agreements with the following parties: Effective May 13, 2024, the Company has engaged Financial Buzz Media Networks LLC ("FBMN") for...

at 18:25
Pint Pharma Announces the Approval of ORLADEYO® (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Mexico
It is with great pleasure that we announce the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks...

at 18:03
Kelyniam Global Releases Q1 Financials
Kelyniam Global , a maker of custom cranial implants, today announced results for its quarter ended March 31, 2024.  Financial highlights for the three months ended March 31, 2024 and the same period in 2023 include:  Total revenue of $957,447...

More news about Health...


News published on and distributed by: